Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ProQR Therapeutics N.V.

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Second Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces First Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Year End 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Third Quarter 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Therapeutics Provides Update on Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Second Quarter 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces First Quarter 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Upcoming Investor Conferences in April and May
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
From ProQR Therapeutics N.V.
Via GlobeNewswire
Tickers PRQR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.